Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - duloxetine hydrochloride, quantity: 33.65 mg - capsule, enteric - excipient ingredients: titanium dioxide; triethyl citrate; hypromellose phthalate; sucrose; indigo carmine; hypromellose; gelatin; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution; maize starch - duloxetine capsules are indicated for the treatment of major depressive disorder (mdd).,treatment of diabetic peripheral neuropathic pain (dpnp). treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 66.8 mg (equivalent: sunitinib, qty 50 mg) - capsule - excipient ingredients: sodium lauryl sulfate; titanium dioxide; croscarmellose sodium; shellac; povidone; magnesium stearate; sodium hydroxide; gelatin; iron oxide black; iron oxide red; propylene glycol; mannitol; iron oxide yellow - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 33.4 mg (equivalent: sunitinib, qty 25 mg) - capsule - excipient ingredients: sodium hydroxide; titanium dioxide; mannitol; shellac; sodium lauryl sulfate; iron oxide red; propylene glycol; povidone; croscarmellose sodium; magnesium stearate; gelatin; iron oxide black; iron oxide yellow - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sunitinib malate, quantity: 16.7 mg (equivalent: sunitinib, qty 12.5 mg) - capsule - excipient ingredients: sodium hydroxide; propylene glycol; shellac; sodium lauryl sulfate; iron oxide red; mannitol; magnesium stearate; titanium dioxide; povidone; gelatin; croscarmellose sodium - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dimethyl fumarate, quantity: 240 mg - capsule, enteric - excipient ingredients: magnesium stearate; methacrylic acid copolymer; triethyl citrate; silicified microcrystalline cellulose; purified talc; croscarmellose sodium; colloidal anhydrous silica; titanium dioxide; indigo carmine; purified water; iron oxide yellow; gelatin; polysorbate 80; sodium lauryl sulfate - it is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dimethyl fumarate, quantity: 240 mg - capsule, enteric - excipient ingredients: croscarmellose sodium; triethyl citrate; silicified microcrystalline cellulose; methacrylic acid copolymer; magnesium stearate; colloidal anhydrous silica; purified talc; titanium dioxide; indigo carmine; purified water; iron oxide yellow; gelatin; polysorbate 80; sodium lauryl sulfate - it is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dimethyl fumarate, quantity: 120 mg - capsule, enteric - excipient ingredients: silicified microcrystalline cellulose; triethyl citrate; croscarmellose sodium; magnesium stearate; purified talc; methacrylic acid copolymer; colloidal anhydrous silica; titanium dioxide; indigo carmine; purified water; iron oxide yellow; gelatin; polysorbate 80; sodium lauryl sulfate - it is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dimethyl fumarate, quantity: 120 mg - capsule, enteric - excipient ingredients: magnesium stearate; methacrylic acid copolymer; silicified microcrystalline cellulose; purified talc; croscarmellose sodium; colloidal anhydrous silica; triethyl citrate; titanium dioxide; indigo carmine; purified water; iron oxide yellow; gelatin; polysorbate 80; sodium lauryl sulfate - it is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dimethyl fumarate, quantity: 120 mg - capsule, enteric - excipient ingredients: croscarmellose sodium; magnesium stearate; methacrylic acid copolymer; triethyl citrate; purified talc; silicified microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; indigo carmine; purified water; iron oxide yellow; gelatin; polysorbate 80; sodium lauryl sulfate - it is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - dimethyl fumarate, quantity: 240 mg - capsule, enteric - excipient ingredients: methacrylic acid copolymer; purified talc; silicified microcrystalline cellulose; triethyl citrate; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; titanium dioxide; indigo carmine; purified water; iron oxide yellow; gelatin; polysorbate 80; sodium lauryl sulfate - it is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.